Literature DB >> 23861514

Radiotherapy of human sarcoma promotes an intratumoral immune effector signature.

Anu Sharma1, Beata Bode, Gabriela Studer, Holger Moch, Michal Okoniewski, Alexander Knuth, Lotta von Boehmer, Maries van den Broek.   

Abstract

PURPOSE: The tumor immune microenvironment plays a crucial role in the development and progression of cancer. Sarcomas are a group of heterogeneous soft tissue malignancies that are often treated with radiotherapy as a part of the treatment concept. There is increasing evidence that radiotherapy leads to alterations in the tumor microenvironment, particularly with respect to the immune infiltrate. This study has been carried out to develop a better understanding of such changes following radiotherapy. EXPERIMENTAL
DESIGN: We retrospectively analyzed the expression of 35 immune response-related genes by quantitative reverse transcription PCR analysis and immunohistochemistry on paired formalin-fixed paraffin-embedded tumor samples from 38 sarcoma patients before and after radiotherapy.
RESULTS: We observed that radiotherapy results in a significant upregulation of several immune effectors and cancer-testis antigens and a concomitant downregulation of immune suppressors, indicating that radiotherapy may support the immune defense in sarcomas.
CONCLUSIONS: These novel findings may have implications for the design of therapeutic regimens which exploite the immune system in sarcoma patients by combining standard radiotherapy with immunotherapeutic strategies. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23861514     DOI: 10.1158/1078-0432.CCR-13-0352

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Authors:  Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

Review 2.  Immunotherapeutic approaches to sarcoma.

Authors:  Melissa Burgess; Hussein Tawbi
Journal:  Curr Treat Options Oncol       Date:  2015-06

3.  Radiotherapy supports tumor-specific immunity by acute inflammation.

Authors:  Laura Surace; Nicole Angelika Scheifinger; Anurag Gupta; Maries van den Broek
Journal:  Oncoimmunology       Date:  2015-06-24       Impact factor: 8.110

4.  Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.

Authors:  Matthew Alderdice; Philip D Dunne; Aidan J Cole; Paul G O'Reilly; Darragh G McArt; Vicky Bingham; Marc-Aurel Fuchs; Stephen McQuaid; Maurice B Loughrey; Graeme I Murray; Leslie M Samuel; Mark Lawler; Richard H Wilson; Manuel Salto-Tellez; Vicky M Coyle
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

Review 5.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

Review 6.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 7.  Trial Watch: Radioimmunotherapy for oncological indications.

Authors:  Norma Bloy; Jonathan Pol; Gwenola Manic; Ilio Vitale; Alexander Eggermont; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 8.  Immunotherapy in Sarcoma: Future Horizons.

Authors:  Melissa Burgess; Vikram Gorantla; Kurt Weiss; Hussein Tawbi
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

9.  Older age impacts radiotherapy-related outcomes in soft tissue sarcoma.

Authors:  Noah K Yuen; Chin-Shang Li; Arta M Monjazeb; Dariusz Borys; Richard J Bold; Robert J Canter
Journal:  J Surg Res       Date:  2015-06-16       Impact factor: 2.192

10.  Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.

Authors:  Emily Z Keung; Melissa Burgess; Ruth Salazar; Edwin R Parra; Jaime Rodrigues-Canales; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; Steven Attia; Richard F Riedel; James Hu; Scott H Okuno; Dennis A Priebat; Sujana Movva; Lara E Davis; Damon R Reed; Alexandre Reuben; Christina L Roland; Denise Reinke; Alexander J Lazar; Wei-Lien Wang; Jennifer A Wargo; Hussein A Tawbi
Journal:  Clin Cancer Res       Date:  2020-01-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.